MAPT and Alzheimer disease: The CSF levels of β amyloid (βA) peptides, total tau (t-tau), and phosphorylated tau (p-tau) have been accepted as molecular biomarkers in the diagnosis of AD (Anoop et al., 2010; Blennow et al., 2015; Blennow, 2017; Khoury and Ghossoub, 2019).